Skip to main content

Redmile Group — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

104
Companies
$12.5B
Total invested
$136.1M
Avg. check
17
Industries
Biotechnology 23Health Care 18Therapeutics 13Medical 10Biopharma 6Pharmaceutical 6+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 104
Krystal Biotech
May 2023

Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..

Biopharma · Pittsburgh$160.0M Post-IPO Equity
Redx Pharma
May 2022

Redx Pharma is a drug discovery and development company.

Biotechnology · Macclesfield$43.6M Post-IPO Equity
Boundless Bio
May 2023

Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.

Biotechnology · La Jolla$100.0M Series C
Atara Biotherapeutics
May 2026

Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.

Biotechnology · South San Francisco$550K Post-IPO Equity
Oruka Therapeutics
April 2026

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$700.4M Post-IPO Equity
Orbital Therapeutics
April 2023

Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.

Alternative Medicine · Cambridge$270.0M Series A
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
Gritstone bio
April 2024

Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.

Biotechnology · Emeryville$32.5M Post-IPO Equity
Scholar Rock
March 2026

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Biopharma · Cambridge$100.0M Post-IPO Debt
Ambrosia Biosciences
March 2026

Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.

Biopharma · Boulder$100.0M Series B
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post-IPO Equity
Ovid Therapeutics
March 2026

Ovid Therapeutic's purpose is to solve intractable medical problems.

Biopharma · New York$60.0M Post-IPO Equity
MedAvail
March 2023

MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products.

Biotechnology · Mississauga$16.0M Post-IPO Equity
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post-IPO Debt
Abcuro
February 2025

Abcuro develops immunotherapies to treat autoimmunity and cancer.

Biotechnology · Newton$200.0M Series C
Bambusa Therapeutics
February 2025

Bambusa Therapeutics operates as biotechnology company.

Biotechnology · Boston$90.0M Series A
Attralus
February 2024

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.

Biopharma · San Francisco$56.0M Series B
OncoResponse
May 2023

OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.

Biopharma · Seattle$14.0M Series D
Wave Life Sciences
December 2025

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases

Biotechnology · Boston$350.0M Post-IPO Equity
Pliant Therapeutics
January 2023

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Biotechnology · South San Francisco$287.5M Post-IPO Equity
Hookipa Pharma
December 2023

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.

Biotechnology · New York$14.4M Post-IPO Equity
EmployerDirect Healthcare
December 2023

EmployerDirect Healthcare is a supplemental healthcare benefit that directs planned medical procedures to high-quality providers.

Health Care · Dallas$92.0M Secondary Market
Syros Pharmaceuticals
December 2023

Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.

Biotechnology · Watertown$45.0M Post-IPO Equity
Kalaris Therapeutics (formerly AlloVir)
December 2025

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Biotechnology · Houston$50.0M Post-IPO Equity

Where Redmile Group invests

Biotechnology23
Health Care18
Therapeutics13
Medical10
Biopharma6
Pharmaceutical6

About Redmile Group's portfolio

How many companies has Redmile Group invested in?

Redmile Group has invested in 104 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Redmile Group invest in?

Redmile Group's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 17 different industry categories.

What is Redmile Group's largest investment?

Among tracked funding rounds, Oruka Therapeutics received $700.4M in a Post-IPO Equity round. Redmile Group's total known invested capital is $12.5B.

What is the average investment size for Redmile Group?

Redmile Group's average investment size is $136.1M across its portfolio of 104 companies.

What are Redmile Group's most recent investments?

Recent Redmile Group portfolio additions include Krystal Biotech, Redx Pharma, Boundless Bio, Atara Biotherapeutics, Oruka Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 104 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →